A

AbbVie

Global biopharmaceutical company developing medicines

Statistics Intern - PhD

Summer 2026Updated
No salary listed
Internship
PhD
Waukegan, IL, USA
In PersonInterns may be assigned to North Chicago, Bay Area, or Florham Park locations; flexibility around location.
Data & AnalyticsData Science

About the job

Requirements
  • Currently enrolled in university, pursuing a PhD in statistics, biostatistics, bioinformatics, biomedical engineering, data science, or other closely related field
  • Must be enrolled in university for at least one semester following the internship
  • Must have completed at least two full years of PhD study prior to the start of the internship
Responsibilities
  • Gain knowledge about the pharmaceutical industry, conduct research on one or more statistical topics, and support other projects as needed
  • Present project/assignment results and learnings to department leadership and the broader Stats organization at the conclusion of the internship
Desired Qualifications
  • Expected graduation date between December 2026 – June 2027

About the company

A

AbbVie

View
Website

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, IL

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Apogee acquisition closed in 2026, expanding AbbVie’s immunology pipeline beyond Skyrizi and Rinvoq.
  • EU approvals for RINVOQ and EPKINLY in September 2026 broaden ex-U.S. revenue.
  • JUVMO launches in October 2026, adding a fresh neuroscience revenue line.

What critics are saying

  • Humira, Skyrizi, and Rinvoq concentration keeps AbbVie exposed if immunology growth slows in 2027.
  • Niaspan antitrust MDL and Biocell ALCL settlements carried $1.7 billion litigation accrual by June 2026.
  • Generic ubrogepant and atogepant suits threaten Ubrelvy and Qulipta exclusivity within years.

What makes AbbVie unique

  • Skyrizi and Rinvoq anchor AbbVie’s post-Humira immunology franchise across 11 EU RINVOQ indications.
  • JUVMO’s September 28, 2026 FDA approval gives AbbVie first-in-class Parkinson’s D1/D5 therapy.
  • AbbVie pairs blockbuster cash flows with Apogee, Iambic, and Valkai deal-making.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options
  • Flexible Work Hours
  • Professional Development Budget

Growth & Insights and Company News

6 month growth

3%

1 year growth

4%

2 year growth

4%
Yahoo Finance
Nov 2nd, 2026
AbbVie vs Bristol Myers Squibb: AbbVie wins for 2027 with $61.2B revenue and growth drivers

The Motley Fool's Brendan Coffey picks AbbVie over Bristol Myers Squibb as the better healthcare stock for 2027, citing AbbVie's stronger near-term growth. AbbVie's 2025 revenue rose about 8.6% to $61.2 billion, with net income of $4.2 billion. It expects sales of $67.2 billion and net income of $14.6 billion this year, driven by immunology drugs Skyrizi and Rinvoq. Bristol Myers Squibb's 2025 revenue was flat at $48.2 billion, but net income reached $7.1 billion after a prior-year loss. It trades at a forward price-to-earnings ratio of 9.7x, against 21.2x for AbbVie. Coffey calls Bristol Myers a turnaround story with a hard-to-predict recovery. Both companies face patent expirations and pricing pressure.

Yahoo Finance
Nov 2nd, 2026
Exxon, Chevron, AbbVie, JPMorgan: four quarterly dividend payers, from 1.79% to 2.77% yields

Four large dividend payers (Exxon Mobil, Chevron, AbbVie, and JPMorgan Chase) offer income backed by cash flow and earnings, according to a 24/7 Wall St analysis. Exxon has raised its dividend for 44 consecutive years. It yields 2.26%, and the payout uses about 73% of free cash flow. The quarterly dividend rose to $1.07 from $1.03. Chevron has the highest yield at 2.77%, but its dividend equals roughly 103% of trailing earnings. It depends most on oil prices. AbbVie raised its quarterly dividend about 5.2% to $1.82, using about 65% of free cash flow. It yields 2.24%. JPMorgan raised its quarterly dividend to $1.65 from $1.50. The payout takes about 28% of earnings, the lowest of the four, with a forward yield of about 1.95%.

Yahoo Finance
Nov 2nd, 2026
AbbVie Q3: $17.4B revenue, 10.3% growth, and analysts probe SKYRIZI, RINVOQ and obesity plans

AbbVie posted third-quarter revenue of $17.4 billion, up 10.3% year on year and in line with analyst estimates of $17.34 billion. Adjusted earnings per share were $3.82, beating the $3.77 forecast. Operating margin rose to 36% from 12.1% a year earlier. Management kept its full-year adjusted earnings guidance at $13.97 per share at the midpoint. Chief executive officer Rob Michael said "nine key products delivered double-digit growth," led by immunology drugs SKYRIZI and RINVOQ and neuroscience drug VRAYLAR. Analysts asked about SKYRIZI's expected market share, RINVOQ payer talks, the obesity pipeline, and business development. Michael pointed to bolt-on deals in core areas. AbbVie trades at $294.17, close to $291.46 before the results. Its market capitalisation is $521.1 billion.

Benzinga
Oct 30th, 2026
AbbVie raises 2026 outlook, boosts dividend.

AbbVie raises 2026 outlook, boosts dividend. Stock score locked: want to see it? Benzinga Rankings give you vital metrics on any stock - anytime. AbbVie Inc. (NYSE:ABBV) stock hit a new 52-week high Friday after the pharmaceutical company reported better-than-expected third-quarter 2026 results and raised its full-year outlook. AbbVie reported third-quarter sales of $17.404 billion, up 10.3% year over year on a reported basis and 10.5% on an operational basis, beating the Wall Street estimate of $17.314 billion. Adjusted earnings of $3.82 per share topped the analyst consensus estimate of $3.75. Immunology and neuroscience drive growth. AbbVie's immunology portfolio generated $9.165 billion in sales, up 16.3% year over year, or 16.6% on an operational basis. Skyrizi sales climbed 22.7% to $5.776 billion, while Rinvoq sales jumped 23.9% to $2.706 billion. Humira sales fell 31.2% to $683 million. Neuroscience revenue rose 19.4% to $3.389 billion, led by Vraylar sales of $1.068 billion, up 14.3%. Botox Therapeutic generated $1.08 billion in revenue. Oncology revenue increased 0.8% to $1.696 billion. Venclexta sales rose 10.7% to $803 million, while Imbruvica sales declined 26.1% to $522 million. Elahere revenue jumped 31% to $224 million. Aesthetics revenue declined 1.4% to $1.176 billion, including a 1.8% decrease on an operational basis. AbbVie raises dividend and highlights growth strategy. AbbVie increased its quarterly dividend 5.2% to $1.82 per share from $1.73, payable Feb. 16, 2027. "AbbVie continues to deliver outstanding results, reflecting solid execution across our diverse portfolio," said Robert Michael, chairman and CEO. Michael highlighted key regulatory approvals, positive clinical data and the acquisition of Apogee Therapeutics as drivers of AbbVie's long-term growth potential. AbbVie raises 2026 sales and earnings forecasts. AbbVie raised its full-year 2026 revenue forecast to $67.8 billion from $67.6 billion, above the Wall Street estimate of $67.585 billion. The updated outlook includes Skyrizi sales of $21.8 billion and Rinvoq sales of $10.3 billion, reflecting higher expectations for both treatments. AbbVie also raised its neuroscience revenue forecast by $300 million to $13 billion, including $4.2 billion each from Vraylar and Botox Therapeutic and $3.1 billion from oral CGRP products. The company increased its oncology revenue forecast to $6.6 billion, reflecting higher expected Venclexta sales of $3.1 billion, partly offset by lower Imbruvica sales of $2.1 billion. AbbVie maintained its aesthetics revenue forecast at $5 billion, with expected Botox Cosmetic sales of $2.8 billion offsetting weakness in other aesthetics products. The company raised its 2026 adjusted earnings forecast to $13.95-$13.99 per share from $13.76-$13.96, above the analyst consensus estimate of $13.93. ABBV Price Action: AbbVie shares were up 1.93% at $296.41 at the time of publication on Friday. The stock is trading at a new 52-week high, according to Benzinga Pro data.

Yahoo Finance
Oct 30th, 2026
CDs yield 1.76% while AbbVie lifts its dividend to $1.82: which suits retirees?

AbbVie raised its quarterly dividend to $1.82 from $1.73 per share on October 30, 2026, a raise no certificate of deposit (CD) can match. The national average yield on a 12-month CD was 1.76% as of October 1, 2026, and a bank cannot cut that rate during the term. Dividends carry risk, though. Companies can cut payouts, and share prices can fall. Johnson & Johnson has raised its dividend for 64 straight years, and Procter & Gamble for 70. Tax also matters. CD interest is taxed as ordinary income, while qualified dividends face rates of 0%, 15%, or 20%. That edge disappears inside a traditional individual retirement account (IRA).

INACTIVE